Back to news

AbbVie Rises on Fresh SKYRIZI Data and Supportive Analyst Tone

Investivoq PriceTracker

AbbVie Inc. (ABBV) is up 3.1% today. Here is some analysis on what might have caused this price movement.

Analysis: The most likely driver appears to be fresh positive Phase 3 data for subcutaneous SKYRIZI in Crohn’s disease, which adds to the company’s case that its next-generation immunology franchise can keep powering growth. The move may also have been helped by a run of supportive analyst price-target updates in recent sessions, reinforcing confidence ahead of AbbVie’s October 30, 2026 earnings report.

Details:

  • AbbVie announced new Phase 3 AFFIRM results on October 13 showing subcutaneous SKYRIZI produced higher clinical and endoscopic response rates than placebo in adults with moderately to severely active Crohn’s disease.
  • Additional updates on October 11 highlighted new SKYRIZI and RINVOQ data in inflammatory bowel disease, keeping investor attention on AbbVie’s largest post-Humira growth engines.
  • Recent analyst actions have stayed constructive, with several firms maintaining positive ratings and some raising price targets during the first half of October.
  • An October 5 filing updated 2026 earnings guidance to reflect an acquired IPR&D and milestones expense, so today’s gain suggests investors were more focused on pipeline strength and long-term revenue drivers than on that near-term cost item.

    • Sources:

    AbbVie, SEC, Benzinga

    Disclaimer: This price movement analysis was generated with the help of AI. Please double-check the information provided for mistakes.

    $ABBV Insider Trading Activity

    ABBV Insider Trades

    $ABBV insiders have traded $ABBV stock on the open market 1 times in the past 6 months. Of those trades, 0 have been purchases and 1 have been sales.

    Here’s a breakdown of recent trading of $ABBV stock by insiders over the last 6 months:

    • NICHOLAS DONOGHOE (EVP, CHIEF BUS/STRAT OFFICER) sold 32,710 shares for an estimated $8,177,500

    To track insider transactions, check out Investivoq's insider trading dashboard. You can access data on insider stock transactions through the Investivoq API insider transaction endpoint.

    EARLY ACCESS
    Receive ABBV Data Alerts
    Real-time alerts on filings, insider trades, and market signals — before everyone else.
    Get Alerts →

    $ABBV Hedge Fund Activity

    We have seen 2,094 institutional investors add shares of $ABBV stock to their portfolio, and 1,658 decrease their positions in their most recent quarter.

    Here are some of the largest recent moves:

    • JPMORGAN CHASE & CO added 47,862,796 shares (+inf%) to their portfolio in Q2 2026, for an estimated $12,044,193,985
    • SIXTH STREET PARTNERS MANAGEMENT COMPANY, L.P. added 12,914,230 shares (+inf%) to their portfolio in Q2 2026, for an estimated $3,249,736,837
    • FRANKLIN RESOURCES INC added 5,373,163 shares (+36.9%) to their portfolio in Q2 2026, for an estimated $1,352,102,737
    • DIAMANT ASSET MANAGEMENT, INC. removed 3,654,526 shares (-99.5%) from their portfolio in Q2 2026, for an estimated $919,624,922
    • CAPITAL WORLD INVESTORS added 3,337,599 shares (+21.1%) to their portfolio in Q2 2026, for an estimated $839,873,412
    • MARSHALL WACE, LLP added 2,989,451 shares (+281757.9%) to their portfolio in Q2 2026, for an estimated $752,265,449
    • SG AMERICAS SECURITIES, LLC added 2,849,663 shares (+251.0%) to their portfolio in Q2 2026, for an estimated $717,089,197

    To track hedge funds' stock portfolios, check out Investivoq's institutional holdings dashboard. You can access data on hedge funds moves and 13F filings through the Investivoq API 13F endpoint.

    $ABBV Congressional Stock Trading

    Members of Congress have traded $ABBV stock 2 times in the past 6 months. Of those trades, 0 have been purchases and 2 have been sales.

    Here’s a breakdown of recent trading of $ABBV stock by members of Congress over the last 6 months:

    • REPRESENTATIVE PETE SESSIONS sold up to $50,000 on 09/14.
    • REPRESENTATIVE JOSH GOTTHEIMER sold up to $15,000 on 05/05.

    To track congressional stock trading, check out Investivoq's congressional trading dashboard. You can access data on congressional stock trades through the Investivoq API Congress trades endpoint.

    $ABBV Price Targets

    Multiple analysts have issued price targets for $ABBV recently. We have seen 7 analysts offer price targets for $ABBV in the last 6 months, with a median target of $273.0.

    Here are some recent targets:

    • Vamil Divan from Guggenheim set a target price of $261.0 on 07/09/2026
    • Chris Schott from JP Morgan set a target price of $280.0 on 07/09/2026
    • Carter Gould from Cantor Fitzgerald set a target price of $265.0 on 07/06/2026
    • Gary Nachman from Canaccord Genuity set a target price of $273.0 on 06/23/2026
    • David Amsellem from Piper Sandler set a target price of $298.0 on 06/23/2026
    • Gavin Clark-Gartner from Evercore ISI Group set a target price of $235.0 on 05/15/2026
    • Terence Flynn from Morgan Stanley set a target price of $278.0 on 04/30/2026

    This article is not financial advice. See Investivoq's disclaimers for more information. Note that there may be inaccuracies due to mistakes in ticker-mapping, and other anomalies.